Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.60 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.60 |
| ▸ | NPC1L1 | Q9UHC9 | 10/20 | 0.59 |
| ▸ | USP2 | O75604 | 2/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | INPP5D | Q92835 | 2/20 | 0.59 |
| ▸ | CDC25A | P30304 | 3/20 | 0.48 |
| ▸ | POLA1 | P09884 | 1/20 | 0.47 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.46 |
| ▸ | CDC25B | P30305 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14007452 | 0.88 | NPC1L1 (0.70) | CYP2D6CYP2C19NPC1L1USP2LMNA | |
| SCHEMBL13988168 | 0.88 | NPC1L1 (0.70) | CYP2D6CYP2C19NPC1L1USP2LMNA | |
| SCHEMBL131383 | 0.88 | NPC1L1 (0.70) | CYP2D6CYP2C19NPC1L1USP2LMNA | |
| SCHEMBL15107562 | 0.88 | NPC1L1 (0.70) | CYP2D6CYP2C19NPC1L1USP2LMNA | |
| SCHEMBL24632922 | 0.86 | NPC1L1 (0.57) | CYP2D6CYP2C19NPC1L1USP2LMNA | |
| SCHEMBL30088637 | 0.86 | NPC1L1 (0.57) | CYP2D6CYP2C19NPC1L1USP2LMNA | |
| SCHEMBL22872157 | 0.86 | NPC1L1 (0.57) | CYP2D6CYP2C19NPC1L1USP2LMNA | |
| SCHEMBL3466236 | 0.86 | NPC1L1 (0.57) | CYP2D6CYP2C19NPC1L1USP2LMNA | |
| SCHEMBL19746045 | 0.82 | NPC1L1 (0.54) | CYP2D6CYP2C19NPC1L1USP2LMNA | |
| SCHEMBL3137808 | 0.82 | NPC1L1 (0.54) | CYP2D6CYP2C19NPC1L1USP2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772003-B2 | Lipid derivatives of aminoglycosides | AVENTIS PHARMA S.A. (FR) | 2010-08-10 | — | — | US | claimed |
| US-7641914-B2 | for forming conjugates (liposomes, complexes, nanoparticles) with biologically active substances and releasing them into cellular tissues or acidic compartments, or for use as nonionic surfactant for stabilizing particles encapsulating biodrugs | GENCELL, S.A. (FR) | 2010-01-05 | — | — | US | claimed |
| EP-1430074-B1 | AMINOGLYCOSIDE LIPID DERIVATIVES FOR TRANSFECTION | AVENTIS PHARMA SA (FR) | 2009-05-06 | — | — | EP | claimed |
| EP-0984925-B1 | COMPOUNDS, PREPARATION AND USE FOR TRANSFERRING NUCLEIC ACIDS INTO CELLS | AVENTIS PHARMA SA (FR) | 2004-12-08 | — | — | EP | claimed |
| US-20030054556-A1 | Lipid derivatives of aminoglycosides | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2003-03-20 | — | — | US | claimed |
| EP-0986568-B1 | NOVEL CLASS OF NUCLEIC ACID CATIONIC TRANSFECTING AGENTS | AVENTIS PHARMA SA (FR) | 2002-03-20 | — | — | EP | claimed |
| US-6300321-B1 | LIPOPOLYAMINES | AVENTIS PHARMA S.A. (FR) | 2001-10-09 | — | — | US | claimed |
| EP-2069500-B1 | COMPOSITIONS COMPRISING A SIRNA AND LIPIDIC 4,5-DISUBSTITUTED 2-DEOXYSTREPTAMINE RING AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF | CENTRE NAT RECH SCIENT (FR) | 2014-09-24 | — | — | EP | disclosed |
| EP-2331071-A1 | NOVEL MULTIMODULAR ASSEMBLY USEFUL FOR INTRACELLULAR DELIVERY | Institut National De La Sante Et De La Recherche Medicale (FR) | 2011-06-15 | — | — | EP | disclosed |
| US-7772003-B2 | Lipid derivatives of aminoglycosides | AVENTIS PHARMA S.A. (FR) | 2010-08-10 | — | — | US | disclosed |
| WO-2010026537-A1 | NOVEL MULTIMODULAR ASSEMBLY USEFUL FOR INTRACELLULAR DELIVERY | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2010-03-11 | — | — | WO | disclosed |
| US-20100035974-A1 | COMPOSITIONS COMPRISING A SIRNA AND LIPIDIC 4,5-DISUBSTITUTED 2-DEOXYSTREPTAMINE RING AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS (FR) | 2010-02-11 | — | — | US | disclosed |
| US-7641914-B2 | for forming conjugates (liposomes, complexes, nanoparticles) with biologically active substances and releasing them into cellular tissues or acidic compartments, or for use as nonionic surfactant for stabilizing particles encapsulating biodrugs | GENCELL, S.A. (FR) | 2010-01-05 | — | — | US | disclosed |
| US-20050222434-A1 | Acid-sensitive compounds, their preparation and uses | GENCELL S.A. | 2005-10-06 | — | — | US | disclosed |
| US-20050085426-A1 | Acid-sensitive compounds, preparation and use thereof | GENCELL S.A.S. (FR) | 2005-04-21 | — | — | US | disclosed |
| US-6812218-B2 | TRANSFERRING NUCLEIC ACIDS TO CELLS | GENCELL S.A. (FR) | 2004-11-02 | — | — | US | disclosed |
| US-20030065033-A1 | Lipid derivatives of polythiourea | GENCELL S.A. (FR) | 2003-04-03 | — | — | US | disclosed |
| US-20030054556-A1 | Lipid derivatives of aminoglycosides | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2003-03-20 | — | — | US | disclosed |
| US-20020091242-A1 | Acid-sensitive compounds, their preparation and uses | GENCELL S.A. (FR) | 2002-07-11 | — | — | US | disclosed |
| US-6300321-B1 | LIPOPOLYAMINES | AVENTIS PHARMA S.A. (FR) | 2001-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222434-A1 | Acid-sensitive compounds, their preparation and uses | LIPA, PHOSPHO1, ACP1 | CYP2D6 4255/4885CYP2C19 4516/4885NPC1L1 76/4885 |
| US-20030065033-A1 | Lipid derivatives of polythiourea | ABCB4, TENT4A, PEBP1 | CYP2D6 4300/4885CYP2C19 4570/4885NPC1L1 64/4885 |
| US-20050085426-A1 | Acid-sensitive compounds, preparation and use thereof | LIPA, PHOSPHO1, ABHD16A | CYP2D6 4102/4885CYP2C19 4403/4885NPC1L1 57/4885 |
| US-20020091242-A1 | Acid-sensitive compounds, their preparation and uses | LIPA, PHOSPHO1, ACP1 | CYP2D6 4255/4885CYP2C19 4516/4885NPC1L1 76/4885 |
| US-20100035974-A1 | COMPOSITIONS COMPRISING A SIRNA AND LIPIDIC 4,5-DISUBSTITUTED 2-DEOXYSTREPTAMINE RING AMINOGLYCOSIDE DERIVATIVES AND USES THEREOF | STARD3, NSUN3, NR1H4 | CYP2D6 2757/4885CYP2C19 4599/4885NPC1L1 329/4885 |
| US-20030054556-A1 | Lipid derivatives of aminoglycosides | TRDMT1, PLIN3, ACSS2 | CYP2D6 3836/4885CYP2C19 4657/4885NPC1L1 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.